「primary」の検索結果

Selects the aldosterone-to-renin ratio (ARR) method over hypokalemia for screening hypertensive patients for primary aldosteronism. Use when a clinician asks what test to use for screening hypertensive patients with resistant hypertension or unexplained hypokalemia for PA.

日本語の概要は準備中です。原文の説明を表示しています。

Determines whether to screen a patient with hypertension for primary aldosteronism based solely on the presence of hypertension. Use when a clinician asks whether to screen a hypertensive patient for PA, triggered by phrases such as "should we screen for aldosteronism" or "evaluate for secondary hypertension".

日本語の概要は準備中です。原文の説明を表示しています。

This skill outlines monitoring of mineralocorticoid replacement in primary adrenal insufficiency, focusing on clinical assessment of salt craving, postural hypotension, or edema alongside serum electrolyte measurements. It is initiated when evaluating patients on fludrocortisone therapy to ensure adequate dosing and avoid over- or under-replacement.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initiating glucocorticoid therapy in all patients with confirmed primary adrenal insufficiency (PAI). Use when PAI diagnosis is confirmed by subnormal cortisol response to ACTH stimulation test or elevated ACTH with low cortisol.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends fludrocortisone 100 µg daily for children with primary adrenal insufficiency and confirmed aldosterone deficiency; for infants under 12 months, adds sodium chloride supplementation. Triggered by PAI with aldosterone deficiency, evidenced by salt craving, hyponatremia, hyperkalemia, or elevated renin with low aldosterone.

日本語の概要は準備中です。原文の説明を表示しています。

Initiates a 6‑month trial of DHEA replacement in women with primary adrenal insufficiency (PAI) who have persistent low libido, depressive symptoms, or low energy despite otherwise optimized glucocorticoid and mineralocorticoid therapy. If the patient does not report a sustained beneficial effect after 6 months, discontinue DHEA.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends increasing hydrocortisone dose in pregnant patients with primary adrenal insufficiency based on individual clinical course, especially during the third trimester. Trigger phrases include "fatigue, postural hypotension, weight loss, or hyperglycemia in pregnant PAI patient" and "need for glucocorticoid dose adjustment in third trimester."

日本語の概要は準備中です。原文の説明を表示しています。

Suggests avoiding synthetic, long-acting glucocorticoids (e.g., prednisolone, dexamethasone) in children with primary adrenal insufficiency (PAI). Use when selecting glucocorticoid replacement for a child with PAI to prevent Cushingoid side effects and dose titration difficulties.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends against dexamethasone for glucocorticoid replacement in primary adrenal insufficiency (PAI) due to risk of Cushingoid side effects from difficult dose titration. Use when selecting a glucocorticoid for PAI management to avoid iatrogenic Cushing syndrome.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests adjusting glucocorticoid dose according to severity of illness or magnitude of the stressor in patients with primary adrenal insufficiency. Use when patient with PAI has intercurrent illness, fever, or stress.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests using hydrocortisone 15–25 mg or cortisone acetate 20–35 mg daily in two or three divided oral doses for adult primary adrenal insufficiency (PAI) patients initiating glucocorticoid replacement. The highest dose is given upon awakening, with the second dose either early afternoon (≈2 h after lunch) or split into lunch and afternoon doses; consider total daily dose calculation based on chosen formulation and frequency.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends measurement of plasma ACTH to establish primary adrenal insufficiency (PAI) diagnosis in patients with confirmed cortisol deficiency; a plasma ACTH concentration ≥2-fold the upper limit of the reference range supports PAI. Use when evaluating plasma ACTH in a patient with low morning cortisol or abnormal corticotropin stimulation test.

日本語の概要は準備中です。原文の説明を表示しています。

The Endocrine Society guideline recommends against routine hormonal monitoring of glucocorticoid replacement in primary adrenal insufficiency and advises adjusting therapy solely based on clinical response. Use when evaluating glucocorticoid dose adequacy, such as when patients report fatigue, weight loss, hypotension, or signs of Cushingoid over-replacement.

日本語の概要は準備中です。原文の説明を表示しています。

This skill guides annual evaluation of patients with primary adrenal insufficiency (PAI) for symptoms and signs of glucocorticoid and mineralocorticoid over- or under-replacement. Use during annual follow-up when assessing for weight changes, blood pressure abnormalities, edema, or symptoms such as fatigue, insomnia, or salt craving.

日本語の概要は準備中です。原文の説明を表示しています。

Set absolute LDL-C, non-HDL-C, and ApoB treatment goals, PLUS percent LDL-C reduction, for a primary-prevention patient on lipid-lowering therapy per the re-introduced treatment goals in the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers goals by PREVENT-ASCVD category (low / borderline / intermediate / high), by CAC score, in severe hypercholesterolaemia / FH, in diabetes with multiple ASCVD risk factors, and the ApoB targets once LDL-C and non-HDL-C goals are met. Use when a clinician asks what LDL goal to aim for, LDL target for intermediate risk, non-HDL goal, ApoB target, dual goals on statin, patient at goal or not, how low should LDL go, statin not enough what next. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Decide when to order coronary artery calcium (CAC) scoring in a primary-prevention patient and interpret the result per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers the Class 1 indication (men ≥40 / women ≥45, borderline / intermediate PREVENT-ASCVD risk, uncertainty about LLT), CAC score interpretation (0, 1–99, 100–299, ≥300, ≥1000), how CAC modifies LDL and non-HDL goals, when to repeat CAC, and pitfalls (incidental CAC on non-cardiac CT, radiation, cost). Use when a clinician asks should I order a CAC score, CAC indications, what does CAC 150 mean, treatment goals with CAC score, repeat CAC frequency, CAC in a smoker, CAC vs CCTA, is CAC useful in intermediate risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

The primary tool for code-navigation questions in ANY language (frontend or backend) — walk the structural graph from an entry point (page, route, handler, command, `main`) down through imports to the IO boundary (network call, query, file read). Use this skill, in preference to the Explore agent or global grep, whenever the user asks "where does X come from?", "what API/data populates Y?", "what renders or wraps the Z panel?", "which file for feature F?", "how is this wired up?", or any code-navigation question mapping a UI element, route, or feature concept to source files. Also reverse queries ("what uses /api/foo?", "who consumes this service?"). Keyword search routinely picks up unrelated flows sharing a domain word and produces wrong answers; the walk follows the actual graph. The JS/TS `walk.mjs`/`discover.mjs` are an optional accelerator, not required — the walk is language-agnostic.

日本語の概要は準備中です。原文の説明を表示しています。

Investigate a question against high-trust primary sources and capture the findings as a Markdown file in the repo. Use when the user wants a topic researched, docs or API facts gathered, or reading legwork delegated to a background agent.

日本語の概要は準備中です。原文の説明を表示しています。

Design relational database schemas (and choose when to go NoSQL) that stay maintainable and fast. Use this skill whenever the user mentions tables, DDL, entities and relationships, normalization (1NF/2NF/3NF), primary and foreign keys, UUID vs bigint IDs, indexes (B-tree, composite, covering, partial), EXPLAIN, constraints (CHECK, UNIQUE, exclusion), transactions and isolation levels, migrations (Alembic, Prisma, Flyway, expand-contract, backfilling), or SQL vs NoSQL (MongoDB, DynamoDB, Cassandra, graph databases). Also trigger for "design the database", "model this domain", "which database should I use", or writing ORM models and migration files for PostgreSQL, MySQL, SQLite, or SQL Server.

日本語の概要は準備中です。原文の説明を表示しています。

When turning a locked still + blueprint into a provider-tuned motion prompt — camera, primary + secondary motion, physics, native-audio sync. Triggers 'motion prompt for Veo/Kling/Sora'.

日本語の概要は準備中です。原文の説明を表示しています。

When shaping the primary message, supporting proofs and audience-by-message matrix from a locked positioning frame — before any copy or launch beat. Triggers on 'tighten the message stack'.

日本語の概要は準備中です。原文の説明を表示しています。

Use this Canvas-owned clean-room skill when a spreadsheet file is the primary input or output. Trigger for `.xlsx`, `.xls`, `.xlsm`, `.csv`, `.tsv`, workbooks, templates, trackers, models, dashboards, charts, formulas, data cleaning, formatting, validation, recalculation, and Google Sheets-targeted handoff.

日本語の概要は準備中です。原文の説明を表示しています。

Load this skill whenever the project contains navigation components — primary navigation menus, dropdown menus, mega menus, breadcrumbs, pagination, mobile hamburger menus, or in-page jump navigation. Under no circumstances create navigation without proper landmark roles, keyboard support, and accessible labels. Absolutely always wrap navigation in <nav> with a unique aria-label.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing, reviewing, or implementing Apple-platform toolbars — current-screen actions vs sidebar navigation, one primary action per screen, overflow menus, protected destructive actions, and keyboard shortcuts.

日本語の概要は準備中です。原文の説明を表示しています。